Ois Podcast

European investment in ophthalmology MedTech is more opportunistic than strategic says Klaus Stockemann, managing partner of Peppermint VenturePartners in Berlin. With fewer venture capitalists focused on the market, they are more receptive to cold calls and impromptu pitches at medical conferences.That’s one of the many insights provided when new OIS Podcast host Sophia Pathai, MD, PhD, MPH caught up with three top-tier VCs who focus on ophthalmology devices and technology.After recalling their nonlinear backgrounds, Stockemann;  Diana Saraceni, cofounder of Panakes Ventures (Milan); and Jennifer McMahon, a partner at Seroba VC (Dublin) discussed the activity in the MedTech space as of late. One piece of news that got Western Europe talking: Belgium-based iStar’s strategic alliance with AbbVie.What else? The guests agreed that ophthalmology’s active, entrepreneurial spirit, the high demand for microtized surgical devices, and the strong M&A market all make for an exciting time to invest in ophthalmology.